ライフサイエンスコーパス: etanercept

1 (53.4%) patients (all p<0.0001 vs placebo or etanercept).

2 s compared with TNF receptor fusion protein (etanercept).

3 mg vs etanercept and p=0.0010 for 100 mg vs etanercept).

4 olizumab), and an IgG1-TNFR2 fusion protein (etanercept).

5 mg vs etanercept and p=0.0663 for 100 mg vs etanercept).

6 (41.6%) patients (all p<0.0001 vs placebo or etanercept).

7 ive cohort (160 treated with adalimumab, 171 etanercept).

8 ial samples were tested (414 adalimumab, 421 etanercept).

9 and function of infliximab, adalimumab, and etanercept.

10 reased risk was observed with ustekinumab or etanercept.

11 both studies and were similar to those with etanercept.

12 ed by treatment with the TNF-alpha inhibitor etanercept.

13 was comparable to the results obtained with etanercept.

14 esence of TNFRI-AlbudAb, control-AlbudAb, or etanercept.

15 before and during therapy with infliximab or etanercept.

16 pruritic cutaneous eruption while receiving etanercept.

17 vitro by the competitive TNFalpha antagonist etanercept.

18 apy and those randomized to receive MTX plus etanercept.

19 size, and a possibly subtherapeutic dose of etanercept.

20 Fifty percent of these patients had received etanercept.

21 cted by conventional anti-TNF treatment with etanercept.

22 authorization requirements for adalimumab or etanercept.

23 locked by addition of the TNF decoy receptor etanercept.

24 ated with juvenile idiopathic arthritis than etanercept.

25 rakizumab 100 mg, 156 to placebo, and 313 to etanercept.

26 par with the effect of blocking TNF-alpha by etanercept.

27 collagen-induced arthritis were treated with etanercept.

28 er 12 weeks were similar for tofacitinib and etanercept.

29 5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisol

30 mg of ustekinumab and in 70.0% who received etanercept; 1.9%, 1.2%, and 1.2%, respectively, had seri

31 as follows: non-biologic, 14.2 (11.5-17.4); etanercept, 15.3 (11.6-20.1); adalimumab, 13.9 (11.4-16.

32 , sphingosine kinase 1 deletion prevents and etanercept (2-week treatment initiated 6 weeks after myo

33 Day 28 complete response rates were etanercept 26%, MMF 60%, denileukin 53%, and pentostatin

34 onth than those who received saline (50%) or etanercept (42%) (P = 0.09).

35 dences of severe infections were as follows: etanercept 48%, MMF 44%, denileukin 62%, and pentostatin

36 mong patients who did not have a response to etanercept, 48.9% had at least 75% improvement in the PA

37 ab 200 mg, tildrakizumab 100 mg, placebo, or etanercept 50 mg (2:2:1:2).

38 Etanercept 50 mg once weekly is an optimal dosage in mos

39 ept 50 mg twice weekly (n = 160) or MTX plus etanercept 50 mg once weekly plus a placebo (n = 40) for

40 ptimal responders to treatment with MTX plus etanercept 50 mg once weekly were given MTX plus etanerc

41 r 10 mg twice daily at about 12 h intervals, etanercept 50 mg subcutaneously twice weekly at about 3-

42 ercept 50 mg once weekly were given MTX plus etanercept 50 mg twice weekly (n = 160) or MTX plus etan

43 aily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was superior to placeb

44 332 to tofacitinib 10 mg twice daily, 336 to etanercept 50 mg twice weekly, and 108 to placebo).

45 e daily dose did not show non-inferiority to etanercept 50 mg twice weekly.

46 ween tofacitinib (10 mg two times a day) and etanercept (50 mg biweekly), and by response status at w

47 b (40 mg subcutaneously every other week) or etanercept (50 mg per week subcutaneously) according to

48 ustekinumab (at weeks 0 and 4) or high-dose etanercept (50 mg twice weekly for 12 weeks).

49 onse system to receive subcutaneous placebo, etanercept (50 mg twice weekly), or one injection of 80

50 healthy levels upon effective treatment with etanercept, a biological drug targeting the TNF pathway

51 combined GEE model including adalimumab and etanercept, a body-mass index of 30 kg/m(2) or more was

52 However, treatment of CD patients with etanercept, a decoy receptor that binds soluble TNF, fai

53 in RA patients responding to treatment with etanercept, a modified TNF receptor-Fc fusion protein.

54 Etanercept, a soluble tumor necrosis factor receptor, ha

55 e blockade of tumor necrosis factor (TNF) by etanercept, a soluble version of the human TNF receptor

56 At week 12, 57% of patients receiving etanercept achieved PASI 75, as compared with 11% of tho

57 eumatoid arthritis, coverage was extended to etanercept, adalimumab, and anakinra in addition to the

58 49 per 100 patient-years in the ustekinumab, etanercept, adalimumab, and infliximab cohorts, respecti

59 Etanercept, adalimumab, and infliximab were similar in t

60 ing between non-biologic systemic therapies, etanercept, adalimumab, and ustekinumab for the treatmen

61 1; and 994 participants were included in the etanercept, adalimumab, ustekinumab cohorts, respectivel

62 increase in serious infections compared with etanercept (aHR, 1.26 [95% CI, 1.07-1.47]) and adalimuma

63 ee patients during treatment with open-label etanercept; all resolved without sequelae.

64 3 mg/kg/week], maximum dosage 1 mg/kg/week), etanercept alone (0.8 mg/kg/week, maximum dose 50 mg), o

65 te the long-term safety and effectiveness of etanercept alone or in combination with methotrexate (MT

66 Etanercept also reduced levels of acute-phase reactants,

67 terleukin-12 and interleukin-23 blocker) and etanercept (an inhibitor of tumor necrosis factor alpha)

68 Renal interstitial administration of Etanercept, an inhibitor of TNFalpha, significantly atte

69 n with lifelong TRAPS in whom treatment with etanercept and anakinra had failed, was administered toc

70 tly various types of TNF antagonists such as etanercept and infliximab have been used successfully.

71 Small studies of etanercept and infliximab have showed these TNF-alpha bl

72 ary metabolite changes distinguished between etanercept and infliximab treatment.

73 or necrosis factor alpha antagonists such as etanercept and infliximab, as well as with interleukin r

74 Etanercept and methotrexate combination is more effectiv

75 oups (-2.1 with triple therapy and -2.3 with etanercept and methotrexate, P=0.26); triple therapy was

76 , P=0.26); triple therapy was noninferior to etanercept and methotrexate, since the 95% upper confide

77 ab groups vs placebo; p<0.0001 for 200 mg vs etanercept and p=0.0010 for 100 mg vs etanercept).

78 ab groups vs placebo; p=0.0031 for 200 mg vs etanercept and p=0.0663 for 100 mg vs etanercept).

79 s in demographic characteristics between the etanercept and placebo groups.

80 % and 65% for patients initially assigned to etanercept and placebo, respectively.

81 ches effective for human psoriasis, that is, Etanercept and Rosiglitazone, are effective in alleviati

82 aseline between the group receiving MTX plus etanercept and the group receiving oral triple therapy (

83 ween subjects randomized to receive MTX plus etanercept and those randomized to triple therapy, regar

84 syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing th

85 g were efficacious compared with placebo and etanercept and were well tolerated in the treatment of p

86 models, as well as selective TNF blockade by etanercept and XPro1595 in wild-type mice, demonstrate t

87 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secu

88 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secu

89 ncies associated with the use of infliximab, etanercept, and adalimumab in children in whom therapy w

90 ed with successful narrow band UVB (NB-UVB), etanercept, and anti-IL-17 treatments.

91 , and 21.6 per 100 patient-years in the MTX, etanercept, and etanercept plus MTX groups, respectively

92 , and 294 patients were enrolled in the MTX, etanercept, and etanercept plus MTX groups, respectively

93 nally associated with the use of infliximab, etanercept, and in a lesser extent adalimumab.

94 cluding ustekinumab, infliximab, adalimumab, etanercept, and nonbiologics (with or without methotrexa

95 gnificant skin and nail disease, adalimumab, etanercept, and ustekinumab are strongly recommended, an

96 (64.6-76.5) vs placebo; 36.9% (29.1-44.7) vs etanercept]) and 291 (75.4%; [68.7% (62.3-75.0) vs place

97 75.6-86.0) vs placebo; 47.2% (39.9-54.4) vs etanercept]) and 310 (80.5%; [73.8% (67.7-79.9) vs place

98 (69.5-80.8) vs placebo; 35.9% (28.2-43.6) vs etanercept]) and 325 (84.2%; [76.9% (71.0-82.8) vs place

99 82.9-91.8) vs placebo; 48.1% (41.2-55.0) vs etanercept]) and 336 (87.3%; [80.0% (74.4-85.7) vs place

100 Abatacept (CTLA4-Ig), etanercept (anti-TNF), or phosphate-buffered saline were

101 Anti-TNF therapy with etanercept appears to further increase the risk of malig

102 Biologics such as etanercept are the most successful drugs used in anti-cy

103 2 weeks; UNCOVER-2 and UNCOVER-3 also had an etanercept arm (50 mg twice weekly).

104 ks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly

105 It can be induced by etanercept, but has also been described during adalimuma

106 patients (69.2%), biologic agents (primarily etanercept) by 106 (27.2%), acitretin by 57 (14.6%), cyc

107 concomitant use of acitretin, the dosing of etanercept can be reduced to maintain similar levels of

108 d the tumor necrosis factor-alpha inhibitor, etanercept, combined with corticosteroids in treating 15

109 Tofacitinib and etanercept commonly reduced IL-6, CCL20, and CXCL10, but

110 High etanercept concentrations were associated with better tr

111 ted that the TNF-alpha-neutralizing molecule etanercept could be an effective treatment for patients

112 Here, we hypothesized that response to etanercept could be monitored by radionuclide imaging in

113 of both forms of tumour necrosis factor with etanercept does not result in protection.

114 Protocols with daclizumab or etanercept during induction had higher rates of II and l

115 study was to generate a panel of mAbs toward etanercept (ETN) and to determine ETN and anti-ETN conce

116 lammation, we used the TNF-alpha antagonist, etanercept (ETN), for studies in syngeneic rat hepatocyt

117 ever, this could not be attributed solely to etanercept exposure during the trial.

118 the OLE, for a total of 318 patient-years of etanercept exposure.

119 s reported in patients with > or =5 years of etanercept exposure.

120 The removal of the N-glycans from etanercept facilitated the selective characterization of

121 ctively inhibited vascular permeability, and etanercept failed to affect either outcome.

122 were noted for functional capacity, in which etanercept fared worse than the other treatments: steroi

123 llowup period, patients continued to receive etanercept for a median of 3.3 years, with a number of p

124 in atopic dermatitis, safety and efficacy of etanercept for the treatment of psoriasis in children, n

125 re observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points)

126 placebo group and 151 patients (48%) in the etanercept group (p<0.0001 for comparisons of both tildr

127 placebo group and 149 patients (48%) in the etanercept group (p<0.0001 for comparisons of both tildr

128 an BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and

129 w solid malignancies were detected, 8 in the etanercept group and 5 in the placebo group.

130 ur (2.4%) and 13 (6.7%) patients; and in the etanercept group by 129 (36.0%) and 159 (41.6%) patients

131 ur (2.4%) and 14 (7.3%) patients; and in the etanercept group by 149 (41.6%) and 204 (53.4%) patients

132 rtality rate was significantly higher in the etanercept group compared with the placebo group (57.7%

133 ation, the risk of solid malignancies in the etanercept group was increased (SIR 3.92 [95% confidence

134 0 in the tofacitinib 10 mg group, 335 in the etanercept group, and 107 in the placebo group).

135 tinib 10 mg group, 222 (66.3%) of 335 in the etanercept group, and 16 (15.0%) of 107 in the placebo g

136 facitinib 10 mg group, 11 (3%) of 335 in the etanercept group, and four (4%) of 107 patients in the p

137 tinib 10 mg group, 197 (58.8%) of 335 in the etanercept group, and six (5.6%) of 107 in the placebo g

138 itinib 10 mg group, seven (2%) of 335 in the etanercept group, and two (2%) of 107 in the placebo gro

139 baseline differences between the placebo and etanercept groups in demographics or disease severity pa

140 However, patients continuing to receive etanercept had reduced symptoms at followup.

141 risk of serious infection were observed for etanercept (hazard ratio [HR] = 1.10, 95% CI = 0.75-1.60

142 As compared with adalimumab, patients on etanercept (HR 1.63; 95% CI: 1.45-1.84) or infliximab (H

143 gic systemic therapies or methotrexate-only (etanercept: HR = 1.47, 95% CI = 0.95-2.28; adalimumab: H

144 of sulfasalazine plus hydroxychloroquine (or etanercept, if necessary, after 6 months) is a reasonabl

145 ment arms: immediate treatment with MTX plus etanercept, immediate oral triple therapy (MTX plus sulf

146 ults suggest that the combination of EXN and etanercept improve engraftment and long-term islet survi

147 a phase 3 clinical trial of tofacitinib and etanercept in adults with moderate-to-severe psoriasis.

148 rofiles during treatment with infliximab and etanercept in RA and PsA may reflect distinct mechanisms

149 her tildrakizumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis.

150 h each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% w

151 h each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% w

152 tment with the TNFalpha signaling inhibitor, etanercept, indicating the involvement of TNFalpha in th

153 07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and

154 Adalimumab, etanercept, infliximab and tocilizumab all showed statis

155 A total of 1,283 RA patients receiving etanercept, infliximab, or adalimumab therapy were studi

156 We identified new users of anti-TNF therapy (etanercept, infliximab, or adalimumab) or nonbiologic di

157 rexate, cyclosporine, acitretin, adalimumab, etanercept, infliximab, or ustekinumab or phototherapy f

158 therapy approved for psoriasis (adalimumab, etanercept, infliximab, ustekinumab) with the possibilit

159 Systemic administration of Etanercept inhibited MHC-I(high) melanoma growth in immu

160 line nor the TNF-alpha-neutralizing compound etanercept inhibited the induction of hyperexcitability

161 te administration of the TNF-alpha inhibitor etanercept inhibits carbon tetrachloride (CCL4)-induced

162 erapy has failed, treatment with adalimumab, etanercept, intralesional corticosteroids, ustekinumab,

163 Etanercept is a highly glycosylated therapeutic Fc-fusio

164 rtality rate after 6 months, indicating that etanercept is not effective for the treatment of patient

165 gents such as infliximab and adalimumab, and etanercept is not effective for treatment of Crohn's dis

166 Although long-term adherence to etanercept is poor, continuing to receive etanercept may

167 with infliximab demonstrating no benefit and etanercept leading to encouraging results warranting fur

168 Moreover, treatment of psoriasis with etanercept led to significantly decreased IL-1F5, -1F6,

169 tioned as F(ab')2 fragments, whereas cleaved etanercept lost its ability to neutralize TNF.

170 to etanercept is poor, continuing to receive etanercept may provide continued symptomatic benefit.

171 ce, -0.52 [CI, -1.85 to 0.81]; P = 0.44) and etanercept (mean difference, -0.92 [CI,-2.28 to 0.44]; P

172 -1.26 [95% CI, -2.79 to 0.27]; P = 0.11) or etanercept (mean difference, -1.01 [CI, -2.60 to 0.58];

173 orse than the other treatments: steroids vs. etanercept (mean difference, -16.16 [CI, -26.05 to -6.27

174 ong-term perspective, an initial strategy of etanercept-methotrexate and biologics with similar cost

175 The ICERs for first-line etanercept-methotrexate and triple therapy were $2.7 mil

176 alysis: The within-trial analysis found that etanercept-methotrexate as first-line therapy provided m

177 Etanercept-methotrexate first versus triple therapy firs

178 al found triple therapy to be noninferior to etanercept-methotrexate in patients with active rheumato

179 To determine the cost-effectiveness of etanercept-methotrexate versus triple therapy as a first

180 lifetime analysis suggested that first-line etanercept-methotrexate would result in 0.15 additional

181 a moderate quality of evidence compared with etanercept monotherapy (Psoriasis Area and Severity Inde

182 erapy (the EM/EM group; n = 111) or received etanercept monotherapy (the EM/E group; n = 111) in year

183 Early sustained combination etanercept-MTX therapy was consistently superior to MTX

184 eive methylprednisolone 2 mg/kg per day plus etanercept, mycophenolate mofetil (MMF), denileukin dift

185 d with anti-TNF medications (total n = 1050, etanercept n = 455, infliximab n = 450), we investigated

186 Data for patients on adalimumab (n=1,879), etanercept (n=1,098), infliximab (n=96), and ustekinumab

187 ned to receive subcutaneous placebo (n=168), etanercept (n=358), or ixekizumab every 2 weeks (n=351)

188 andomly assigned to receive placebo (n=193), etanercept (n=382), ixekizumab every 2 weeks (n=385), or

189 ce registry (n = 1,239; adalimumab, n = 538; etanercept, n = 104; ustekinumab, n = 597).

190 0), anti-tumor necrosis factor-a (TNF-alpha; etanercept, n=50), or cyclosporine treatment (n=50).

191 60 given placebo, and 14 (1.9%) of 739 given etanercept; no deaths were noted.

192 h polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methot

193 in those injected with conventional MSCs or etanercept only.

194 y to be non-adherent compared to those using etanercept or adalimumab (29.2% vs. 16.4%; P </= 0.001).

195 term cyclosporine use has been combined with etanercept or adalimumab to control psoriasis flares.

196 5 mg/week) and stable dose of TNF inhibitor (etanercept or adalimumab) for >/= 12 weeks were randomiz

197 Combining biologics, such as etanercept or adalimumab, with phototherapy likely resul

198 of other long-term studies and suggest that etanercept or etanercept plus MTX has an acceptable safe

199 of subjects who initiated biologic therapy (etanercept or infliximab) and reported consistent use at

200 monotherapy or combination therapy (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroq

201 o one of the combination therapies (MTX plus etanercept or MTX plus sulfasalazine plus hydroxychloroq

202 en up to 6 subcutaneous injections of either etanercept or placebo for 3 weeks.

203 compare two tofacitinib doses with high-dose etanercept or placebo in this patient population.

204 odds ratio (OR) = 1.50, P(corr) = 0.050) and etanercept (OR = 1.64, P(corr) = 0.016).

205 Therapeutically antagonizing TNF (etanercept) or S1P (JTE013) signaling corrects this defe

206 2 epidural injections of steroids, etanercept, or saline, mixed with bupivacaine and separa

207 gimens had greater efficacy than placebo and etanercept over 12 weeks in two independent studies.

208 5 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoria

209 y poorer response compared with TNF-308GG in etanercept (P = 0.001, n = 7) but not infliximab (P = 0.

210 as compared with 49.0% of those who received etanercept (P<0.001 for both comparisons).

211 as compared with 56.8% of those who received etanercept (P=0.01 and P<0.001, respectively).

212 adalimumab, but not the soluble TNF receptor etanercept, paradoxically promoted the interaction betwe

213 wild-type mice, and TNF-alpha blockade with etanercept partially prevented renal atrophy in IRAK-M(-

214 atment of mice with the TNFalpha antagonist, etanercept, partially blunted BCG-induced IDO activation

215 completed 12 month follow-up and none of the etanercept patients.

216 (74.4-85.7) vs placebo; 33.9% (27.0-40.7) vs etanercept]) patients; in the ixekizumab every 4 weeks g

217 (67.7-79.9) vs placebo; 38.9% (31.7-46.1) vs etanercept]) patients; in the ixekizumab every 4 weeks g

218 (62.3-75.0) vs placebo; 33.8% (26.3-41.3) vs etanercept]) patients; in the placebo group by four (2.4

219 (71.0-82.8) vs placebo; 30.8% (23.7-37.9) vs etanercept]) patients; in the placebo group, by four (2.

220 eeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2).

221 onses at weeks 39 and 52 to receive 25 mg of etanercept plus methotrexate (combination-therapy group)

222 centile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4,

223 ne added to methotrexate, was noninferior to etanercept plus methotrexate in patients with rheumatoid

224 results indicate that combined therapy with etanercept plus methotrexate may be beneficial in patien

225 Etanercept plus methotrexate was the only combination th

226 rexate or biologic therapy received 50 mg of etanercept plus methotrexate weekly for 52 weeks (open-l

227 r systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only.

228 e, sulfasalazine, and hydroxychloroquine) or etanercept plus methotrexate.

229 tis within 1 year of combined treatment with etanercept plus methotrexate.

230 one (0.8 mg/kg/week, maximum dose 50 mg), or etanercept plus MTX for 3 years in an open-label, nonran

231 00 patient-years in the MTX, etanercept, and etanercept plus MTX groups, respectively).

232 ts were enrolled in the MTX, etanercept, and etanercept plus MTX groups, respectively.

233 -term studies and suggest that etanercept or etanercept plus MTX has an acceptable safety and effecti

234 4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 pe

235 p (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percen

236 ho had a remission while receiving full-dose etanercept-plus-methotrexate therapy, continuing combina

237 rthritis who had a remission while receiving etanercept-plus-methotrexate therapy.

238 groups received infliximab post-reperfusion; etanercept pre-reperfusion and at postoperative days (PO

239 Etanercept production was verified from the conditioned

240 - and O-glycans and O-glycosylation sites in etanercept provides a basis for future studies addressin

241 Psoriasis patients treated with etanercept rapidly decrease cutaneous IL-17C levels, sug

242 At week 36, after 24 weeks of open-label etanercept, rates of PASI 75 were 68% and 65% for patien

243 Etanercept reduces symptoms and serum levels of inflamma

244 nd MMP12 cleaved infliximab, adalimumab, and etanercept, releasing a 32-kilodalton Fc monomer.

245 by intravitreal injection of bevacizumab or etanercept, respectively.

246 iopharmaceuticals Rituximab, Adalimumab, and Etanercept, respectively.

247 Treatment with the combination of MTX plus etanercept resulted in a statistically significant radio

248 nt of Nlrp3A350V mice with the TNF inhibitor etanercept resulted in all pups surviving to adulthood,

249 Etanercept significantly reduced disease severity in chi

250 ith infliximab (TNF monoclonal antibody) and etanercept (soluble TNF receptor) therapy.

251 uggest that the acceptable safety profile of etanercept therapy is maintained for up to 8 years in th

252 Given concern about a drug-induced eruption, etanercept therapy was discontinued and the cutaneous fi

253 Adalimumab therapy, but not etanercept therapy, induces a potent and stable Treg cel

254 the increase was unaltered after 12 weeks of etanercept therapy.

255 metric assay, prior to and after 12 weeks of etanercept therapy.

256 nditions and following the administration of etanercept (TNF-alpha inhibitor; 1 mg Kg(-1)).

257 reating animals with anti-inflammatory drugs etanercept (TNFalpha inhibitor), anakinra (IL-1 receptor

258 and p38MAPK, while TNFalpha inhibition (with etanercept), TNFalpha gene ablation, or p38 inhibition,

259 udies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specific

260 derwent a second randomization to placebo or etanercept to investigate the effects of withdrawal and

261 The efficacy and safety of a crossover from etanercept to ustekinumab were evaluated after week 12.

262 were similar before and after crossover from etanercept to ustekinumab.

263 Compared with etanercept, tofacitinib showed a wider spectrum of cardi

264 fected with recombinant minicircles encoding etanercept (trade name, Enbrel), which is a tumour necro

265 t percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile po

266 Treg cell number, function, or phenotype in etanercept-treated patients, and Th17 responses remained

267 y greater improvements in WPAI-PSO scores vs etanercept-treated patients: UNCOVER-2: presenteeism, wo

268 TNF(-/-) and TNF-R1(-/-) mice as well as Etanercept-treated WT mice displayed enhanced intratumor

269 erventions (SI-control; n=5) or with EXN and etanercept treatment (SI-EXN; n=4).

270 riasis genes were reversed after 3 months of etanercept treatment in patients who responded to treatm

271 Etanercept treatment of old mice reversed these changes,

272 Etanercept treatment significantly attenuated the total

273 With all of the etanercept treatment strategies, blocking of TNFalpha si

274 (72%) entered the fourth year of continuous etanercept treatment, and 26 patients (45%) entered the

275 Randomisation was stratified by history of etanercept treatment, with a block size of three.

276 Etanercept treatment, with or without methotrexate, may

277 luated to determine the long-term outcome of etanercept treatment.

278 observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 180 patients wit

279 In this retrospective analysis of 2 etanercept trials, disease activity was calculated at ba

280 parably shortly after initiation of MTX plus etanercept, triple therapy, and MTX monotherapy among pa

281 s in mean cholesterol levels in the MTX plus etanercept, triple therapy, and MTX monotherapy arms.

282 d: 31 following infliximab use, 15 following etanercept use, and 2 following adalimumab use.

283 Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Effica

284 ponse to treatment with four specific drugs: etanercept, ustekinumab, adalimumab, and methotrexate.

285 t nail, skin, and joint disease, adalimumab, etanercept, ustekinumab, infliximab, methotrexate, aprem

286 , -5.87 [CI, -15.59 to 3.85]; P = 0.23), and etanercept vs. saline (mean difference, 10.29 [CI, 0.55

287 with moderate to severe alcoholic hepatitis, etanercept was associated with a significantly higher mo

288 We confirmed that self-reproduced etanercept was biologically active in vitro.

289 pth characterization of the glycosylation of etanercept was carried out using liquid chromatography/m

290 Etanercept was first treated with peptide N-glycosidase

291 re-randomised from placebo to tildrakizumab; etanercept was given twice weekly in part 1 of reSURFACE

292 The reporting rates for infliximab and etanercept were compared with the background rate of mal

293 The reporting rates for etanercept were elevated above background for lymphomas

294 Infliximab, adalimumab, and etanercept were incubated with mucosal homogenates from

295 Compared to adalimumab, patients receiving etanercept were more likely to discontinue therapy (haza

296 lity rates of patients receiving placebo and etanercept were similar on an intention-to-treat basis (

297 a and pharmacological blockade of TNF-alpha (Etanercept) were also performed.

298 proaches, whether triple therapy or MTX plus etanercept, were similar.

299 onsidered in these patients in preference to etanercept, which seems to be associated with lower rate

300 Blocking of TNFalpha was performed using etanercept, which was administered subcutaneously at a d